Basilea Pharmaceutica AG (BSLN) CHF1 (Regd)
0.60 CHF
(1.48%)
- Add to watchlist
- This stock can be held in a
0.60 CHF
(1.48%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
0.60 CHF
(1.48%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Business summary
Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.
Contact details
Important dates
General stock information
- Short code:
- BSLN
- ISIN:
- CH0011432447
- Market cap:
- 535.35 million CHF
- Shares in issue:
- 12.12 million
- Sector:
- Biotechnology
- Exchange:
- SIX Swiss Exchange
- Country:
- Switzerland
- Currency:
- Swiss Franc
- Indices:
- Swiss All Share Index
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.